Prime/MRx provides you with regular updates on the drug pipeline as well as next-generation clinical information and hot topics. The following Drug Insights publications for August 2024 will keep you informed on what’s trending now.

Released August 28, 2024

Monthly Clinical News

An overview of clinical insights’ trending topics and timely drug information highlights. This month covers the U.S. Food and Drug Administration’s (FDA) issued  safety alert on dosing errors observed with compounded injectable semaglutide products, as well as illegal sales of semaglutide online.

Monthly Drug Approvals

Monthly drug approvals provides a review of newly approved specialty drugs, recent drug launches and new indications in the last month, including deuruxolitinib (Leqselvi™), paliperidone palmitate (Erzofri®), afamitresgene autoleucel (Tecelra®)  and more.

Released August 27, 2024

Expert Clinical Network Insights

Committed to keeping you informed on the latest specialty drug insights from leading experts, this newsletter features
givinostat (Duvyzat™) delandistrogene moxeparvovec-rokl (Elevidys^®).

Released August 20, 2024

Oncology Insights

Featuring commentary by Simone Ndujiuba on developments in the oncology space, this installment discusses how cancer medications have topped global drug sales and how increased utilization is a major driver of oncology drug sales.

Released August 16, 2024

Drug Watch List

A monthly report of the most notable drugs that may significantly affect the populations we serve. Notable drugs this month are dupilumab (Dupixent®), eladocagene exuparvovec (Upstaza™), govorestatand more.

Released August 15, 2024

High-Cost Therapy Profile

Providing a clinical deep dive into a select high cost drug in the pipeline. This month’s profile features detailed information about intravenous (IV) linvoseltamab.

Released August 14, 2024

FDA Decisions Expected for September 2024

A monthly report of the most notable drugs that may significantly affect the populations we serve. Notable drugs this month are ocrelizumab/hyaluronidase (Ocrevus^®) SC, atezolizumab/hyaluronidase (Tecentriq^®) SC, tradipitant and more.

August FDA Recalls

FDA Recalls

American Health Packaging on behalf of BluePoint Laboratories is voluntarily recalling 21 batches of Potassium
Chloride Extended-Release (ER) capsules in the strength of 750 mg which is equivalent to 10 mEq of potassium. Additionally, Endo has voluntarily recalled one lot of Clonazepam Orally Disintegrating Tablets 0.25 mg. Product may appear as
Clonazepam Orally Disintegrating Tablets 0.125 mg in a 60-count pack.